Role of monteleukast in the treatment of covid – 19 an overview

Abstract

Introduction: COVID – 19 infections that has shaken the world by leading into a significant health issue. World is in the need for effective therapies in order to improve clinical outcomes of patients. We must consider new approaches in the treatment of COVID-19. In order to bring effectiveness in treatment, it is important to know the exact pathogenesis of the virus so that it will pave a path for an efficient treatment.
 Methods: To ensure comprehensive research and discuss the objective of the review of the study, literature collection was collected from the relevant published articles from databases such as “PubMed, Medline, and SCOPUS,”
 Results: COVID-19 is linked with severe inflammation. Pro-inflammatory cytokine levels are elevated in the lung and in bronchial cells. Leukotrienes [LTs] are eicosanoids and inflammatory mediators. Leukotrienes are produced by various cell types which includes, leukocytes. Cysteinyl-leukotrienes (CysLTs) are involved in respiratory pathologies such as inflammation, thrombosis and vascular damage, and fibrotic remodeling.
 Discussion: Hence there is a rational for LTs inhibition and montelukast usage in respiratory diseases beyond asthma. Various literatures suggest the use of LT receptor antagonist ‘Montelukast’ in COVID – 19 treatments.
 Conclusion: This review article will discuss various aspects of Montelukast in COVID – 19 treatments and reviews the properties of montelukast that could be beneficial in the treatment of COVID-19.